Bleomycin in Hodgkin's Lymphoma – A Boon or a Bane? – A Retrospective Study of Bleomycin Pulmonary Toxicity in Hodgkin's Lymphoma

INTRODUCTION: Hodgkin's lymphoma (HL) is one of the most curable malignancies with cure rates of above 85% across all stages. Bleomycin containing regimen is routinely employed in the treatment of HL. Pulmonary toxicity due to this drug is the most feared side effect in these regimens where the...

Descripción completa

Detalles Bibliográficos
Autores principales: Udupa, Chethana Babu K, Koteshwar, Prakashini, Udupa, Karthik S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812434/
https://www.ncbi.nlm.nih.gov/pubmed/31673206
http://dx.doi.org/10.4103/IJPC.IJPC_107_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6812434/
https://www.ncbi.nlm.nih.gov/pubmed/31673206
http://dx.doi.org/10.4103/IJPC.IJPC_107_19

Ejemplares similares